Phibro Animal Health Corp (PAHC) stock
PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 22/3046% below fair value
$34.92−0.10 (-0.29%)
Close on Nov 17, 2026Market cap $1.42BP/E 14.4Yield 1.37%
Phibro Animal Health total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Phibro Animal Health's total debt was $620.52M at Mar 31, 2026. For fiscal 2025 it was $631.69M, up 102.4% from the year before. Over ten years it grew 8.2% a year on average. The highest annual figure on record is $631.69M in fiscal 2025.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | $631.69M | +102.4% |
| FY2024 | Jun 30, 2024 | $312.08M | -6.5% |
| FY2023 | Jun 30, 2023 | $333.84M | +15.9% |
| FY2022 | Jun 30, 2022 | $287.93M | -6.0% |
| FY2021 | Jun 30, 2021 | $306.46M | +29.4% |
| FY2020 | Jun 30, 2020 | $236.76M | +2.9% |
| FY2019 | Jun 30, 2019 | $230.18M | -5.0% |
| FY2018 | Jun 30, 2018 | $242.38M | -2.3% |
| FY2017 | Jun 30, 2017 | $248.14M | -11.7% |
| FY2016 | Jun 30, 2016 | $281.17M | -1.9% |
| FY2015 | Jun 30, 2015 | $286.52M | -1.0% |
| FY2014 | Jun 30, 2014 | $289.39M | -2.8% |
| FY2013 | Jun 30, 2013 | $297.73M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $620.52M | -2.3% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $624.24M | -2.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $627.96M | +112.7% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $631.69M | +102.4% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $635.41M | +98.1% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $639.13M | +97.3% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $295.17M | -10.2% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $312.08M | -6.5% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $320.82M | +11.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $323.90M | +10.8% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $328.87M | +11.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $333.84M | +15.9% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $288.44M | -5.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $292.23M | -4.7% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $296.16M | -3.4% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $287.93M | -6.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $306.62M | +34.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $306.57M | +32.9% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $306.51M | +31.1% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $306.46M | +29.4% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $227.66M | +3.0% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $230.69M | +3.0% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $233.72M | +2.9% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $236.76M | +2.9% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $221.04M | -5.2% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $224.07M | -5.2% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $227.12M | -5.1% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $230.18M | -5.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $233.23M | -4.4% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $236.28M | -3.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $239.33M | -3.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $242.38M | -2.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $243.88M | -12.7% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $245.37M | -12.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $246.85M | -12.0% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $248.14M | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $279.47M | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $280.03M | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $280.60M | – |
See a number that looks wrong?